EP4333979A4 - Procédé de titrage de doses d'agents psychédéliques - Google Patents

Procédé de titrage de doses d'agents psychédéliques

Info

Publication number
EP4333979A4
EP4333979A4 EP22799340.9A EP22799340A EP4333979A4 EP 4333979 A4 EP4333979 A4 EP 4333979A4 EP 22799340 A EP22799340 A EP 22799340A EP 4333979 A4 EP4333979 A4 EP 4333979A4
Authority
EP
European Patent Office
Prior art keywords
psychedelics
titration
dose
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22799340.9A
Other languages
German (de)
English (en)
Other versions
EP4333979A1 (fr
Inventor
Robert Barrow
Daniel R. Karlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mind Medicine Inc
Original Assignee
Mind Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mind Medicine Inc filed Critical Mind Medicine Inc
Publication of EP4333979A1 publication Critical patent/EP4333979A1/fr
Publication of EP4333979A4 publication Critical patent/EP4333979A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Dental Preparations (AREA)
  • Measurement Of Radiation (AREA)
EP22799340.9A 2021-05-03 2022-05-01 Procédé de titrage de doses d'agents psychédéliques Pending EP4333979A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163183579P 2021-05-03 2021-05-03
PCT/US2022/027179 WO2022235529A1 (fr) 2021-05-03 2022-05-01 Procédé de titrage de doses d'agents psychédéliques

Publications (2)

Publication Number Publication Date
EP4333979A1 EP4333979A1 (fr) 2024-03-13
EP4333979A4 true EP4333979A4 (fr) 2025-01-15

Family

ID=83932279

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22799340.9A Pending EP4333979A4 (fr) 2021-05-03 2022-05-01 Procédé de titrage de doses d'agents psychédéliques

Country Status (7)

Country Link
EP (1) EP4333979A4 (fr)
JP (1) JP2024517194A (fr)
AU (2) AU2022268891A1 (fr)
CA (1) CA3216939A1 (fr)
IL (1) IL308068A (fr)
TW (1) TW202245767A (fr)
WO (1) WO2022235529A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
CN117355302A (zh) 2021-04-30 2024-01-05 思维医学股份有限公司 Lsd盐晶体形式
IL308816A (en) 2021-05-25 2024-01-01 Atai Therapeutics Inc New n,n-dimethyltryptamine salts and crystalline salt forms
MX2023014620A (es) 2021-06-09 2024-01-30 Atai Therapeutics Inc Nuevos profarmacos y conjugados de dimetiltriptamina.
JP2024529727A (ja) 2021-08-19 2024-08-08 マインド メディシン， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤
WO2023019369A1 (fr) 2021-08-20 2023-02-23 Pharmala Biotech Inc. Compositions comprenant des mélanges non racémiques de (r)-et (s)-3,4-méthylènedioxyméthamphétamine ou (r) et (s) n-méthyl -1,3-benzodioxolylbutanamine et leurs utilisations
JP2024545787A (ja) 2021-12-30 2024-12-11 アタイ セラピューティクス， インコーポレイテッド 一酸化窒素送達剤としてのジメチルトリプタミン類似体
WO2023168023A1 (fr) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-cristaux ou sels comprenant de la psilocine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170157343A1 (en) * 2014-06-30 2017-06-08 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
WO2020157569A1 (fr) * 2019-01-30 2020-08-06 Diamond Therapeutics Inc. Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur
WO2020169850A1 (fr) * 2019-02-22 2020-08-27 Gh Research Limited 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
WO2021003467A1 (fr) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Compositions de dosage et procédés d'utilisation de composés psychédéliques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170157343A1 (en) * 2014-06-30 2017-06-08 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
WO2020157569A1 (fr) * 2019-01-30 2020-08-06 Diamond Therapeutics Inc. Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur
WO2020169850A1 (fr) * 2019-02-22 2020-08-27 Gh Research Limited 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "How to Microdose: A Step by Step Guide - Microdosing information, research, community, coaching and more.", 30 April 2021 (2021-04-30), pages 1 - 9, XP093230199, Retrieved from the Internet <URL:https://web.archive.org/web/20210430131601/https://microdosinginstitute.com/how-to/how-to-microdose/> *
KUYPERS KIM P.C.: "The therapeutic potential of microdosing psychedelics in depression", vol. 10, 27 August 2020 (2020-08-27), XP093229382, ISSN: 2045-1253, Retrieved from the Internet <URL:https://journals.sagepub.com/doi/pdf/10.1177/2045125320950567> DOI: 10.1177/2045125320950567 *
See also references of WO2022235529A1 *

Also Published As

Publication number Publication date
AU2022268891A1 (en) 2023-11-09
EP4333979A1 (fr) 2024-03-13
TW202245767A (zh) 2022-12-01
AU2025217270A1 (en) 2025-08-28
JP2024517194A (ja) 2024-04-19
WO2022235529A1 (fr) 2022-11-10
CA3216939A1 (fr) 2022-11-10
IL308068A (en) 2023-12-01

Similar Documents

Publication Publication Date Title
EP4333979A4 (fr) Procédé de titrage de doses d&#39;agents psychédéliques
EP4069212A4 (fr) Inhibiteurs de hif-2 alpha
EP3634402C0 (fr) Méthodes de traitement de la fibrose kystique
EP4289996C0 (fr) Techniques d&#39;indexation d&#39;acide nucléique
EP4065114C0 (fr) Méthode de fabrication de la relutrigine/prax-562
EP3277276A4 (fr) Procédés d&#39;administration d&#39;inhibiteurs de glutaminase
EP3538494A4 (fr) Procédé de traitement électrochimique de l&#39;eau
EP3540433A4 (fr) Système permettant d&#39;estimer la concentration d&#39;un agent d&#39;injection dans le sol
EP3893883A4 (fr) Méthodes pour le traitement de la dépression
EP3941921A4 (fr) Méthodes thérapeutiques de traitement de l&#39;hépatite b
EP3897582C0 (fr) Procédé de séchage par pulvérisation de semaglutide
EP3583521A4 (fr) Exécution d&#39;ordres de parts fractionnelles
EP4227290C0 (fr) Procédé de recyclage de dmf
EP3578161A4 (fr) Méthode d&#39;amélioration de la stabilité au stockage d&#39;un produit cosmétique
EP3833752A4 (fr) Procédé de traitement de la mucopolysaccharidose de type ii
EP3426632A4 (fr) Inhibiteurs de l&#39;interaction creb-cbp pour le traitement de la leucémie
EP4395815A4 (fr) Procédé d&#39;amélioration de la stabilité d&#39;inhibiteurs du point de contrôle immunitaire
EP3826664A4 (fr) Procédé de traitement des mucopolysaccharidoses de type i
EP3756133A4 (fr) Procédé d&#39;authentification d&#39;articles
EP3786904C0 (fr) Méthode d&#39;évulation télématique des composants d&#39;un véhicule
EP3816298A4 (fr) Procédé permettant l&#39;évaluation de la cytotoxicité d&#39;un gaz
EP3761207C0 (fr) Procédé de fiabilisation de contenus d&#39;opérations de chaîne de blocs
EP3746102C0 (fr) Procédé d&#39;isolement de cytisine
DE112019002959A5 (de) Verfahren zur Detektion von Kennleuchten
EP3692174A4 (fr) Procédés de traitement de lymphomes

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

TPAA Information related to observations by third parties modified

Free format text: ORIGINAL CODE: EPIDOSCTIPA

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0025000000

Ipc: A61K0031137000

A4 Supplementary search report drawn up and despatched

Effective date: 20241216

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/00 20060101ALI20241210BHEP

Ipc: A61K 31/675 20060101ALI20241210BHEP

Ipc: A61K 31/48 20060101ALI20241210BHEP

Ipc: A61K 31/4045 20060101ALI20241210BHEP

Ipc: A61K 31/137 20060101AFI20241210BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250919

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DEFINIUM THERAPEUTICS US, INC.